Rani Therapeutics (RANI) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 – – Announced a warrant inducement transaction with an existing investor with gross proceeds of $4.3 million ...